Visionary Holdings Business Summary

Visionary Holdings Inc. (GV) is a Nasdaq-listed enterprise currently executing a definitive strategic pivot from its legacy education and real estate roots toward a high-growth model centered on biotechnology, anti-aging, and premium medical aesthetics. The company generates revenue through the sale of advanced regenerative products, such as its flagship Premier Regenerative Complex, and the delivery of AI-enabled health management solutions. As of March 2, 2026, the company has streamlined its operations by divesting its non-core education division to focus exclusively on life sciences, recently securing a $12 million distribution agreement with Huajin China and advancing a $9 million health services contract. Within the small-cap landscape, Visionary competes with diversified service and education providers like Four Seasons Education (FEDU), ATA Creative Inc. (AACG), and JIADE (JDZG), positioning itself as a high-risk turnaround play transitioning into the specialized regenerative medicine sector. Originally founded by Fan Zhou, the company’s leadership underwent a comprehensive restructuring in late 2025 to align with its biotechnology focus, now led by Chief Executive Officer Xiyong Hou and Co-CEO Jun Huang, who jointly oversee global operational optimization and compliance. The executive suite is supported by Chief Financial Officer Xiaolan Liu and Chief Operating Officer Robert Jay Lees, both of whom bring extensive experience in cross-border corporate governance and capital operations. Governance is anchored by Chairman William T. Chai and Vice Chairman Donald M. Kealey, who lead a nine-member board focused on institutionalizing the company’s new 'big health' mandate. This team is currently backed by strategic institutional investors, recently evidenced by a $450,000 convertible debt financing aimed at bolstering liquidity during the company's transition into the Asian and North American medical aesthetics markets.